DG
TEVA icon

Delek Group’s Teva Pharmaceuticals TEVA Stock Holding History

Delek Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$8.09M Sell
876,300
-912,200
-51% -$11M 0.31% 93
2019
Q1 		$28M Buy
1,788,500
+176,600
+11% +$3.11M 1.17% 18
2018
Q4 		$24.9M Buy
1,611,900
+412,300
+34% +$8.45M 1.13% 20
2018
Q3 		$25.8M Buy
1,199,600
+716,100
+148% +$16.6M 1.08% 20
2018
Q2 		$11.8M Buy
483,500
+283,500
+142% +$5.78M 0.5% 69
2018
Q1 		$3.42M Buy
+200,000
New +$3.9M 0.18% 134
2017
Q4 		– Hold
0
– – – 127

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Delek Group's TEVA Position: Q2 2019 in Review

Delek Group increased its Teva Pharmaceuticals (TEVA) stake by 24% in Q2 2019, buying an estimated $14.8M and bringing the position to 6,367,642 shares worth $57.4M. The position accounts for 2.22% of the portfolio, ranked #4.

Delek Group first reported a position in TEVA in Q4 2017 and has held it in 7 quarters since. The position peaked at $80.2M in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Delek Group held 6,367,642 shares of Teva Pharmaceuticals worth $57.4M as of Q2 2019.
  • Delek Group bought 1,230,259 Teva Pharmaceuticals shares in Q2 2019, an estimated $14.8M.
  • Teva Pharmaceuticals made up 2.22% of Delek Group's portfolio in Q2 2019, its #4 holding.
  • Delek Group first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 7 quarters since.
  • Delek Group's Teva Pharmaceuticals position peaked at $80.2M in Q1 2019.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.